ESMO Media Releases

Sarcoma patients show great openness to the use of complementary alternative medicines (CAMs) for supportive care, but they are poorly informed about safety issues and risk of interactions with anti-cancer drugs.

Nearly 1 in 4 patients with advanced cancer, treated at Comprehensive Cancer Care Network (NCCN) centres in the US, are receiving innovative drugs matched to DNA mutations in their tumours.

Reporters are invited to follow the ESMO 2018 Congress, the leading international oncology event in Europe, beginning on Friday 19 October at the Messe München in Munich, Germany.

ESMO, the leading organisation for medical oncology, has revealed the four distinguished oncology professionals who will receive its annual awards during the ESMO 2018 Congress, 19-23 October, Munich, Germany.

Individualised therapies that target the specific genetic features of tumours have the potential to transform cancer diagnosis, treatment and care.

At the ESMO workshop, “Gender medicine meets oncology”, to be held in Lausanne, Switzerland, on 30 November and 1 December 2018, a multidisciplinary faculty of experts will discuss the concepts and methods of gender medicine and their implications for clinical practice and research in oncology.

A new scale for tumour DNA mutations which will simplify and standardise choices for targeted cancer treatment has been agreed by leading cancer specialists in Europe and North America. The scale, called ESCAT (ESMO Scale for Clinical Actionability of molecular Targets), is published this week in the Annals of Oncology.

The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO), the world’s two leading organisations for oncology professionals, today issued a joint statement calling upon governments to renew political commitment to improve cancer services and reduce cancer deaths.

The Molecular Analysis for Personalised therapy (MAP) Congress is a one-of-a-kind meeting designed to answer the critical question about how to integrate in daily practice the wealth of information coming from the analysis of tumour samples.

ESMO 20^th World Congress on Gastrointestinal Cancer celebrates two decades of clinical progress and examines further promising research

ESMO, the leading European professional organisation for medical oncology, has announced that the ESMO 2020 Annual Congress will take place from 18 to 22 September 2020, at the IFEMA – Feria de Madrid, Spain.

Researchers have shown for the first time that a form of artificial intelligence or machine learning known as a deep learning convolutional neural network (CNN) is better than experienced dermatologists at detecting skin cancer.